Azido-Thalidomide

Background Introduction

Azido-Thalidomide is a highly versatile E3 ligase ligand-linker conjugate designed for use in the development of PROTACs (Proteolysis Targeting Chimeras). As a derivative of thalidomide containing an azide functional group, it facilitates modular construction of targeted protein degradation tools for research and drug discovery.

Mechanism

Azido-Thalidomide functions as a cereblon (CRBN) E3 ubiquitin ligase ligand, harnessing the ubiquitin-proteasome system for selective protein degradation. Its azide group enables bioorthogonal ‘click chemistry’ conjugation with a variety of alkyne-modified ligands, allowing rapid and flexible assembly of heterobifunctional PROTAC molecules. Once incorporated into a PROTAC, the thalidomide-based moiety binds to CRBN, recruiting the E3 ligase complex to a target protein, resulting in ubiquitination and proteasomal degradation of the target protein.

Applications

Azido-Thalidomide is ideal for chemical biology and drug discovery applications, particularly in the design and synthesis of next-generation PROTAC molecules. It is widely used for structure-activity relationship (SAR) studies, rapid prototyping of targeting chimeras, functional screening of protein degradation, and validation of novel therapeutic targets. Additionally, it supports the development of custom protein degraders in cancer, neurodegenerative disease, and immunology research.

Azido-Thalidomide serves as a versatile E3 Ligase Ligand-Linker Conjugate in PROTACs, facilitating targeted protein degradation by linking an E3 ligase ligand to a target protein ligand. This molecule effectively bridges the gap between the E3 ligase and the protein of interest, enhancing the specificity and efficacy of degradation processes. The following provides a detailed description of this molecule.

Linker: The linker in Azido-Thalidomide is characterized by its moderate length and azido functionality, offering a balance of flexibility and rigidity. It is designed to be non-cleavable, ensuring stable conjugation between the ligand and the target protein.

Ligand: The ligand component of Azido-Thalidomide is based on thalidomide, a well-established E3 ligase ligand. Its structural characteristics include a phthalimide core, which is crucial for binding with the cereblon E3 ligase, enhancing the degradation of target proteins.

Reactive Site: The azido group in Azido-Thalidomide acts as the reactive site, facilitating click chemistry reactions with alkyne-functionalized target protein ligands. This site is optimal for copper-catalyzed azide-alkyne cycloaddition (CuAAC), promoting efficient and selective conjugation.

Recommended Target Protein Ligand: The ideal warhead for use with Azido-Thalidomide is an alkyne-functionalized molecule. This compatibility allows for precise click chemistry reactions, which are advantageous due to their high specificity and efficiency. Such warheads are particularly useful in applications requiring robust and stable linkages, such as in vitro studies of protein interactions and degradation pathways.